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Abstract
Background: Spontaneous splenic rupture considered a relatively rare but life threatening. The three commonest
causes of spontaneous splenic rupture are malignant hematological diseases, viral infections and local inflammatory
and neoplastic disorders. We describe a unique and unusual case of inflammatory myofibroblastic tumor of the tail
of pancreas presented with massively enlarged spleen and spontaneous splenic rupture.
Case presentation: A 19 years old male patient with no significant past medical history presented to emergency
room with abdominal pain and fatigue. Massively enlarged spleen was detected. Hypotension and rapid reduction
of hemoglobin level necessitated urgent laparatomy. About 1.75 liters of blood were found in abdominal cavity.
A large tumor arising from the tail of pancreas and local rupture of an enlarged spleen adjacent to the tumor were
detected. Distal pancreatectomy and splenectomy were performed. To our knowledge, we report the first case of
massively enlarged spleen that was complicated with spontaneous splenic rupture as a result of splenic congestion
due to mechanical obstruction caused by an inflammatory myofibroblastic tumor of the tail of pancreas. A review
of the literature is also presented.
Conclusion: Inflammatory myofibroblastic tumor of the tail of pancreas should be included in the differential
diagnosis of the etiological causes of massively enlarged spleen and spontaneous splenic rupture.
Introduction
The most common causes of splenomegaly are liver dis-
eases (33%), hematologic malignancies (27%), infections
(23%), congestion or inflammation (8%), primary splenic
diseases (4%) and others (5%) [1]. Cirrhosis, lymphoma,
AIDS and endocarditis, congestive heart failure and
splenic vein thrombosis considered the most common
causes in each variety - respectively [1]. There are only
a few conditions that cause massively enlarged spleen
including chronic myeloid leukemia, hairy cell leukemia,
lymphoma, myelofibrosis, thalassemia major, visceral
leishmaniasis, malaria, tropical splenomegaly syndrome,
AIDS with Mycobacterium avium complex and Gaucher
disease [2]. Spontaneous splenic rupture considered a
relatively rare but life threatening. Recently, Renzulli et
al reported a systematic review of 845 cases with
spontaneous splenic rupture that had been published
over more than 28 years [3]. In 84.1 percent of cases a
single etiological factor was found. Two underlying
pathologies were found in 8.2 percent of cases and three
or more etiological factors were found in 0.7 percent of
cases. The three commonest causes of spontaneous sple-
nic rupture were malignant hematological diseases, viral
infections and local inflammatory and neoplastic disor-
ders. Massively enlarged spleen and spontaneous splenic
rupture caused by inflammatory myofibroblastic tumor
(IMT) of the tail of pancreas is unusual and had been
not reported before.
Case presentation
Written informed consent was obtained from the patient
for publication of this case report. A 19 years old male
patient with no significant past medical history pre-
sented to emergency room with abdominal pain and
fatigue without complains of anorexia, nausea, vomiting,
weight loss, jaundice or fever. Physical examination
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92/min. Abdominal palpation revealed diffuse abdominal
tenderness and splenomegaly 22 cm. The liver and
regional lymph nodes were not palpable. The remaining
physical examination was unremarkable. Computed
tomography (CT) scan of the abdomen showed massive
splenomegaly and a solid mass with hypodense area in
the tail of the pancreas (Figure 1). No liver lesions or
abdominal lymphadenopathy were identified. Blood ana-
lysis revealed hemoglobin 10.6 gr/dl, white blood cell
were 7000/mm
3, platelet count 271000/mm
3.O t h e r
laboratory analysis including potassium, sodium, cal-
cium, magnesium, phosphorus, blood urea nitrogen,
creatinine, serum amylase, lipase, and liver chemistry
were all within normal range. Five hours later, blood
pressure dropped to 86/55 and reduction of hemoglobin
level to 5.9 gr/dl was detected. These findings consid-
ered indications for urgent explorative laparotomy. Sud-
den massive bleeding may cause acute hypovolemic
shock even without reduction in the hemoglobin level.
The patient underwent an urgent explorative laparot-
omy. About 1.75 liters of blood were found in abdom-
inal cavity. A large tumor arising from the tail of
pancreas and local rupture of an enlarged spleen adja-
cent to the tumor were detected. Distal pancreatectomy
and splenectomy were performed. The postoperative
course was without any remarkable complications.
Macroscopic pathology revealed a cystic mass measuring
8.2×6.5×6.0 cm in the tail of the pancreas and huge
spleen measuring 23.5×15.5×6.3 cm (Figure 2). The pan-
creatic tumor was adhered to the hilar region of the
spleen. The wall of the cystic mass was 1.4 cm. Micro-
scopic pathology showed diffuse myofibroblastic prolif-
eration of the wall of the cystic mass with a variable
inflammatory component surrounded by pancreatic par-
enchyma (Figure 3). The patient has been followed for
6 years without any clinical or radiographic evidence of
recurrence.
Discussion
IMT is a histopathologic entity previously known as an
inflammatory pseudotumor which was initially reported
in 1990 in the pulmonary system [4]. Different names
have been used to describe this entity, such as plasma
cell granuloma, plasma cell pseudotumor, inflammatory
fibroxanthoma, inflammatory pseudotumor and histiocy-
toma [5]. The histological features vary slightly from site
to site, which may, at least in part, be related to differ-
ences in the phase of the lesion’s development at the
time of the detection. Representative features include
the presence of a myofibroblastic proliferation and a
varying degree of inflammatory infiltrates, mainly con-
sisting of lymphocytes, histiocytes and plasma cells [6].
A number of the clinical and pathological features of
IMT suggest the possibility that this lesion is more simi-
lar to a neoplasm than an inflammatory lesion [7]. Some
investigators argue that IMT may be a true sarcoma and
prefer the term inflammatory fibrosarcoma [7-9].
Whether IMT and inflammatory fibrosarcoma are actu-
ally the same tumor or different entities, it is remains
controversial. Now, it is generally accepted that IMT is
indeed a true neoplasm with a wide spectrum of histo-
pathological behavior, varying from benign lesions to
rare aggressive tumors [7]. Recently, inflammatory fibro-
sarcoma has become included in the spectrum of
inflammatory myofibroblastic proliferations [10].
Although IMT occurs more frequently in the pulmon-
ary system but it had been described in a wide variety of
other organs [6]. In a clinicopathologic and immunohis-
tochemical study of 84 cases of extrapulmonary IMT,
the involved organs were intra-abdominal sites in 49
cases (58.4%), upper respiratory tract in 9 cases (10.7%),
genitourinary tract in 8 cases (9.5%), trunk in 8 cases
(9.5%), pelvis and retroperitoneum in 4 cases (4.8%),
extremities in 3 cases (3.6%), and head and neck in 3
cases (3.6%) [11-13]. Furthermore, IMT has also been
reported in the orbit [14], salivary glands [15], spleen
[16-18], liver [19,20], urinary bladder and soft tissues
[20,21], skin [22], kidneys [23], heart [24] and central
nervous system [25].
IMT of the pancreas is rare. Only 27 cases of IMT
located in the pancreas have been reported in English
literature [5,6,26-43]. The age distribution of IMT of the
pancreas resembled that of in pulmonary system ranging
2.5 to 70 years. IMT equally affects males and females.
Commonly, the clinical presentation of IMT of the pan-
creas is a mass discovered incidentally by imaging inves-
tigations for other reasons. The presenting symptoms
Figure 1 CT scan of the abdomen showed massive
splenomegaly and a solid mass with hypodense area in the
tail of the pancreas (arrows).
Hassan et al. World Journal of Emergency Surgery 2010, 5:28
http://www.wjes.org/content/5/1/28
Page 2 of 6and signs of pancreatic IMT were abdominal pain
(65.4%), unintentional weight loss (42.3%), jaundice
(38.5%), palpable abdominal mass (26.9%) and anemia
(23.0%). Associated clinical symptoms included fatigue
(11.5%), fever (7.5%), anorexia (7.5%), nausea and vomit-
ing (7.5%).
The presenting symptoms of the reported patient were
abdominal pain and fatigue as a result of massively
enlarged spleen and anemia due to substantial conges-
tion of the spleen resulted from the location of the IMT
in the tail of pancreas that cause a considerable obstruc-
tion of the blood drainage from the spleen. The abdom-
inal pain and the anemia caused mainly by the huge
palpable spleen rather than by the tumor itself. Anor-
exia, nausea, vomiting, weight loss or jaundice, were not
included in the presenting symptoms of our patient. It
w a sr e p o r t e dt h a to n ep a t i e n tw i t hI M Tl o c a t e di nt h e
body and the tail of the pancreas developed splenic vein
thrombosis resulting in splenomegaly, thrombocytopenia
and upper gastrointestinal hemorrhage from isolated
Figure 2 Macroscopic pathology shows huge spleen measuring 23.5 × 15.5 × 6.3 cm and a cystic mass measuring 8.2 × 6.5 × 6.0 cm
located in the tail of the pancreas adhered to the hilar region of the spleen (arrows). Microscopically, red pulp congestion and
hyperplasia of the white pulp are shown in the left lower corner.
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located in the tail of the pancreas developed massively
enlarged spleen as a result of mechanical obstruction
caused by the tumor itself and complicated with abdom-
inal bleeding due to spontaneous splenic rupture. No
thrombosis of splenic vessles was found and no gastric
varices or upper gastrointestinal hemorrhage were
detected. Surprisingly, also no thrombocytopenia or leu-
kopenia, were observed.
The tumor was located in the head of the pancreas in
57.7% of cases, whereas it was found in the body and
the tail of the pancreas in 42.3%. IMT of the pancreas
has a tendency to be a larger in size than that in the
pulmonary system at the time of diagnosis ranging
1.5-13 cm [5,11]. The size of the IMT in the presented
patient was 8.2 × 6.5 × 6.0 cm. Almost all patients
underwent exploratory laparotomy and surgical resec-
tion. However, correct diagnoses were not made in any
Figure 3 Panoramic view of the IMT showing fibrin and cellular debris (A). The inner part is formed by cellular area adjacent to necrotic
and inflammatory material [Intermediate power magnification - Hematoxylin and eosin stain (B)]. The external area of the pancreatic tissue
involved by myofibroblastic cells of the IMT [Low power magnification - Hematoxylin and eosin stain (C)].
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pancreatic resection, even with an intraoperative frozen
section biopsy.
Complete surgical resection is the treatment of choice
for IMT without any need of chemotherapy and radia-
tion therapy [24,44,45]. The prognosis of IMT is gener-
ally good, with only a rare incidence of malignant
transformation [44]. However, a significant recurrence
rate of 25% was reported [11]. IMT of the retroperito-
neum has susceptibility for more aggressive behavior
with multiple recurrences [44]. It was suggested that the
presence of atypia, ganglion-like cells and p53 expres-
sion may suggest more aggressive behavior [46,47].
T h e s el e s i o n sm a yb ei n d i s t i nguishable from inflamma-
tory fibrosarcoma due to a high degree of clinical and
morphological overlap [44]. Radiation therapy [9,48,49],
immunosuppressive therapy [50] and chemotherapy
with or without combined radiation therapy [11,44] had
been considered in the management of aggressive IMT
or inflammatory fibrosarcoma.
Because of a higher recurrence rate, approaching 25%
in extrapulmonary IMT, our patient has been closely
followed with no clinical or radiographic evidence of
recurrence for 6 years following surgery.
Conclusion
Inflammatory myofibroblastic tumor of the tail of pan-
creas should be included in the differential diagnosis of
the etiological causes of massively enlarged spleen and
spontaneous splenic rupture.
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